Kits Eyecare Ltd. KTYCF OTC · Consumer cyclical · Canada
$13.25 -3.71% -$0.51
Summary
49 / 100 · Bulios Score
What speaks for it
- Revenue grew by 30% a year over the last 3 years.
- It holds more cash than debt: $27.4M against $5.15M.
- Analysts expect revenue to grow by 23% this fiscal year.
What to watch
- The share price is above the Bulios Fair Price.
- Out of every 100 CAD of revenue, only 1.9 CAD is left as net profit.
- It earns only 6.2 CAD a year on every 100 CAD of invested capital.
Bulios Scoring describes a company's quality and track record, not its future return. A high score is not a buy signal. Learn more
Score in detailPrice
Is it expensive?
Looks expensiveBy our assumptions the business is worth less than its shares cost today.
Bulios Fair Price is an estimate of a stock's fair value from the Bulios valuation model. It is an input for your own analysis, not investment advice. How does it work?
Today you pay 152.5 CAD for 1 CAD of yearly profit.
Valuation in detailIs it growing?
Yes, fastRevenue (CAD)
Diluted EPS (CAD)
- Analyst estimate
Revenue grew by 22% a year over 5 years. Over the last 3 years it grew by 30% a year. For the next fiscal year analysts expect revenue to grow by 23%.
Growth in detailDoes it make money?
PoorlyWhere 100 CAD of revenue goes
- Cost of sales 62 CAD
- Sales and administration 34 CAD
- Taxes and other 1.4 CAD
- Net profit 1.9 CAD
Net profit, industry median (Specialty Retail) 4.0 CAD
Out of every 100 CAD of revenue, 1.9 CAD is left as net profit.
Profitability in detailIs it financially healthy?
YesIt could repay all its debt from a single year of free cash flow. It holds more cash than debt.
Financial health in detailDoes it pay a dividend?
NoIt pays no dividend.
Dividends in detailWhat do analysts expect?
No coverageNo analyst covers this stock.
Analysts in detailWhat does it earn on?
By product
The company reports no revenue by product.
By region
The company reports no revenue by region.